Skip to content
lifestyle.the-newshub.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AgomAb Therapeutics N.V.
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
May 22, 2026
Agomab Announces Closing of Initial Public Offering
February 12, 2026
Agomab Announces Pricing of Initial Public Offering
February 12, 2026
Agomab Announces Launch of Initial Public Offering
February 10, 2026